Fecal microbiota transplantation through colonoscopy in the treatment of recurrent Clostridioides difficile: Experience at a university center

被引:0
|
作者
Quera, R. [1 ]
Nunez, P. [1 ,2 ]
von Muhlenbrock, C. [1 ,3 ]
Espinoza, R. [4 ]
机构
[1] Univ Los Andes, Clin Univ Los Andes, Ctr Enfermedades Digest, Med Interna, Santiago, Chile
[2] Univ Chile, Hosp San Juan de Dios, Fac Med Occidente, Secc Gastroenterol, Santiago, Chile
[3] Hosp Clin Univ Chile, Dept Med, Secc Gastroenterol, Santiago, Chile
[4] Univ Los Andes, Clin Univ Los Andes, Secc Infectol, Med Interna, Santiago, Chile
来源
REVISTA DE GASTROENTEROLOGIA DE MEXICO | 2024年 / 89卷 / 04期
关键词
Clostridioides difficile; Fecal microbiota transplantation; Colonoscopy; Third age; Pregnancy; INFECTION; DIAGNOSIS; FROZEN; FRESH; RISK;
D O I
10.1016/j.rgmx.2024.03.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction: The majority of cases of Clostridioides difficile infection (CDI) respond to antibiotic treatment. Fecal microbiota transplantation (FMT) has been accepted as an effective treatment in cases of recurrent CDI. Aim: Our aim was to describe the clinical results of FMT performed for the treatment of recurrent CDI. Material and methods: The study was conducted on patients with recurrent CDI treated with FMT through colonoscopy, within the time frame of January 2021 and December 2023. Demographic and clinical data were collected, including pre-FMT treatment data, the FMT success rate, and clinical progression during follow-up. Telephone surveys were carried out to evaluate satisfaction. Results: Thirteen patients with a mean age of 55 years underwent FMT (including 7 patients above 65 years of age and one pregnant woman). Patients presented with a median of 3 previous episodes of CDI (range 2-4). The median time interval from first episode of CDI to FMT was 4 months (range 3-10). The effectiveness of a single FMT session was 100%. During post-FMT follow-up (median of 11 months, range 3-32), 3 patients have presented with a new CDI episode, and a successful second FMT was performed on 2 of them. No adverse events were registered, and all patients had a positive perception of FMT. Conclusions: In the present study, despite its small size, FMT through colonoscopy was shown to be a safe, effective, and lasting therapy in cases of recurrent CDI, concurring with results from larger studies. (c) 2024 Asociacion Mexicana de Gastroenterolog<acute accent>& imath;a. Published by Masson Doyma Mexico S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).
引用
收藏
页码:513 / 520
页数:8
相关论文
共 50 条
  • [41] Metagenomic, metabolomic, and lipidomic shifts associated with fecal microbiota transplantation for recurrent Clostridioides difficile infection
    McMillan, Arthur S.
    Zhang, Guozhi
    Dougherty, Michael K.
    McGill, Sarah K.
    Gulati, Ajay S.
    Baker, Erin S.
    Theriot, Casey M.
    MSPHERE, 2024, 9 (10)
  • [42] Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
    Huus, Kelsey E.
    Frankowski, Marcin
    Pucic-Bakovic, Maja
    Vuckovic, Frano
    Lauc, Gordan
    Mullish, Benjamin H.
    Marchesi, Julian R.
    Monaghan, Tanya M.
    Kao, Dina
    Finlay, B. Brett
    GUT MICROBES, 2021, 13 (01) : 1 - 12
  • [43] Experience with fecal microbiota transplantation in the treatment of Clostridium difficile infection
    Vigvari Szabolcs
    Nemes Zsuzsanna
    Vincze Aron
    Solt Jeno
    Sipos David
    Feiszt Zsofia
    Kappeter Agnes
    Kovacs Beata
    Peterfi Zoltan
    ORVOSI HETILAP, 2014, 155 (44) : 1758 - 1762
  • [44] Gram-Negative Taxa and Antimicrobial Susceptibility after Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
    Steed, Danielle Barrios
    Wang, Tiffany
    Raheja, Divyanshu
    Waldman, Alex D.
    Babiker, Ahmed
    Dhere, Tanvi
    Kraft, Colleen S.
    Woodworth, Michael H.
    MSPHERE, 2020, 5 (05)
  • [45] Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile
    Drewes, Julia L.
    Corona, Alina
    Sanchez, Uriel
    Fan, Yunfan
    Hourigan, Suchitra K.
    Weidner, Melissa
    Sidhu, Sarah D.
    Simner, Patricia J.
    Wang, Hao
    Timp, Winston
    Oliva-Hemker, Maria
    Sears, Cynthia L.
    JCI INSIGHT, 2019, 4 (19)
  • [46] New treatment approaches for Clostridioides difficile infections: alternatives to antibiotics and fecal microbiota transplantation
    Bratkovic, Tomaz
    Zahirovic, Abida
    Bizjak, Marusa
    Rupnik, Maja
    Strukelj, Borut
    Berlec, Ales
    GUT MICROBES, 2024, 16 (01)
  • [47] Treatment of Recurrent Clostridioides difficile Infection Using Fecal Microbiota Transplantation in Iranian Patients with Underlying Inflammatory Bowel Disease
    Azimirad, Masoumeh
    Yadegar, Abbas
    Gholami, Fatemeh
    Shahrokh, Shabnam
    Aghdaei, Hamid Asadzadeh
    Ianiro, Gianluca
    Suzuki, Hidekazu
    Cammarota, Giovanni
    Zali, Mohammad Reza
    JOURNAL OF INFLAMMATION RESEARCH, 2020, 13 : 563 - 570
  • [48] The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model
    Xu, Qiaomai
    Zhang, Shumeng
    Quan, Jiazheng
    Wu, Zhengjie
    Gu, Silan
    Chen, Yunbo
    Zheng, Beiwen
    Lv, Longxian
    Li, Lanjuan
    APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 106 (19-20) : 6689 - 6700
  • [49] Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile
    Tixier, Emily N.
    Verheyen, Elijah
    Luo, Yuying
    Grinspan, Lauren Tal
    Du, Charles H.
    Ungaro, Ryan C.
    Walsh, Samantha
    Grinspan, Ari M.
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (03) : 978 - 988
  • [50] Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules
    Reigadas, E.
    Bouza, E.
    Olmedo, M.
    Vazquez-Cuesta, S.
    Villar-Gomara, L.
    Alcala, L.
    Marin, M.
    Rodriguez-Fernandez, S.
    Valerio, M.
    Munoz, P.
    JOURNAL OF HOSPITAL INFECTION, 2020, 105 (02) : 319 - 324